OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Mayer on Efficacy Findings With Giredestrant Plus Everolimus in ER+/HER2– Advanced Breast Cancer

December 12th 2025

Erica Mayer, MD, MPH, discusses giredestrant plus everolimus vs physician’s choice of endocrine therapy plus everolimus in ER+, HER2-negative locally advanced or metastatic breast cancer.

Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC

December 12th 2025

Pasi A. Jänne, MD, PhD, discusses considerations for selecting a frontline combination regimen in EGFR-mutated NSCLC.

Dr Gonzalez-Martin on the Safety of TUB-040 in Ovarian Cancer

December 12th 2025

Antonio Gonzalez-Martin, MD, discusses the key safety findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Dr Yap on Saruparib/Camizestrant in Advanced ER+, HER2-Negative or HER2-Low Breast Cancer

December 12th 2025

Dr Punie on Patient-Reported Outcomes With Sacituzumab Govitecan vs Chemotherapy in Advanced TNBC

December 11th 2025

Kevin Punie, MD, discusses PRO data from the phase 3 ASCENT-03 trial.

Dr Rugo on Elacestrant-Based Combos in ER+/HER2– Locally Advanced or Metastatic Breast Cancer

December 11th 2025

Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.

Dr Alkassis on Cathepsin Protease Expression and Its OS Association With T-DXd in Metastatic Breast Cancer

December 11th 2025

Samer Alkassis, MD, PhD, discusses how cathepsin protease expression may correlate with survival outcomes to trastuzumab deruxtecan in metastatic breast cancer.

Dr Hamilton on First-Line Tucatinib-Based Maintenance in HER2+ Metastatic Breast Cancer

December 10th 2025

Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.

Dr Tolaney on Implications of Data for Sacituzumab Govitecan in First-line Advanced TNBC

December 10th 2025

Sara Tolaney, MD, MPH, discusses the clinical implications of sacituzumab govitecan in the first-line treatment of advanced triple-negative breast cancer.

Dr Tolaney on the Design of the ELEGANT Trial in ER+, HER2-Negative Early Breast Cancer

December 10th 2025

Sara M. Tolaney, MD, MPH, discusses the design and potential significance of the ongoing ELEGANT trial of elacestrant in ER-positive early breast cancer.

Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML

December 10th 2025

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

Dr Rimm on Conceptual Considerations Surrounding ADC Mechanisms in Breast Cancer

December 10th 2025

David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.

Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL

December 10th 2025

Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr Vincent-Salomon on Persisting Gaps in Clinical Interpretation of Invasive Lobular Carcinoma

December 9th 2025

Anne Vincent-Salomon, PR, MD, PhD, HDR, highlights persistent gaps that continue to challenge reproducibility and clinical interpretation in the diagnostic classification of invasive lobular carcinoma.

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma

December 9th 2025

Lori A. Leslie, MD, discusses 3-year efficacy findings with epcoritamab plus rituximab and lenalidomide in previously untreated follicular lymphoma.

Dr Haddad on the Efficacy of Asciminib in Newly Diagnosed CML

December 9th 2025

Fadi Haddad, MD, discusses the efficacy of asciminib in patients with newly diagnosed chronic myeloid leukemia as seen in a phase 2 trial.

Dr Freedland on the Next Steps for Evaluating Enzalutamide in Prostate Cancer

December 8th 2025

Stephen J. Freedland, MD, discusses future avenues for research with enzalutamide in biochemically recurrent prostate cancer.

Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

December 8th 2025

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma

December 8th 2025

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

December 7th 2025

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.